GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » FCF Margin %

Alphamab Oncology (HKSE:09966) FCF Margin % : -174.06% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alphamab Oncology's Free Cash Flow for the six months ended in Dec. 2023 was HK$-156.7 Mil. Alphamab Oncology's Revenue for the six months ended in Dec. 2023 was HK$90.0 Mil. Therefore, Alphamab Oncology's FCF Margin % for the quarter that ended in Dec. 2023 was -174.06%.

As of today, Alphamab Oncology's current FCF Yield % is -10.30%.

The historical rank and industry rank for Alphamab Oncology's FCF Margin % or its related term are showing as below:

HKSE:09966' s FCF Margin % Range Over the Past 10 Years
Min: -327.84   Med: -257.7   Max: -109.26
Current: -109.26

During the past 7 years, the highest FCF Margin % of Alphamab Oncology was -109.26%. The lowest was -327.84%. And the median was -257.70%.

HKSE:09966's FCF Margin % is ranked better than
53.36% of 1042 companies
in the Biotechnology industry
Industry Median: -139.2 vs HKSE:09966: -109.26

Alphamab Oncology FCF Margin % Historical Data

The historical data trend for Alphamab Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology FCF Margin % Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial - - -327.84 -257.70 -109.26

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -140.54 -393.75 -193.36 -70.17 -174.06

Competitive Comparison of Alphamab Oncology's FCF Margin %

For the Biotechnology subindustry, Alphamab Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's FCF Margin % falls into.


Alphamab Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alphamab Oncology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-261.438/239.29
=-109.26 %

Alphamab Oncology's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-156.704/90.028
=-174.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » FCF Margin %
Comparable Companies
HKSE:06660 HKSE:01541 HKSE:09969 HKSE:01952 HKSE:02315 HKSE:06955 HKSE:02105 HKSE:06855 HKSE:02480 HKSE:02696 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
3NK:Germany
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024
Website
https://www.alphamabonc.com
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
Executives
South Dakota Trust Company Llc 2301 Trustee
Xu Ting 2305 Beneficiary of a trust
Liu Yang 2307 Founder of a discretionary trust who can infl
Rubymab Ltd. 2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines